drugset / Trial / NCT00237588
Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)
RandomizedCrossoverDouble-blind
Summary
To determine if angiotensin-II AT-1 receptor blockade(ARB) may improve insulin sensitivity assessed by the hyperinsulinaemic isoglycaemic glucose clamp, more than CCB therapy at a comparable dose with regards to the blood pressure-lowering effect.
Timeline
- Start
- 2004-12
- Primary completion
- —
- Completion
- 2005-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlodipine | Other / unclassified | 5 mg | — |
| Subject | Amlodipine | Other / unclassified | 10 mg | — |
| Subject | Losartan | Other / unclassified | 100 mg | — |